Meningococcal Group ACYW135 (Conjugate) (MCV4)

Phase 1Biologic

Meningococcal Group ACYW135 (Conjugate) (MCV4) is one of 19 biologic programs targeting Influenza. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfluenzaActive, not recruiting

InfluenzaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Preclinical

16 2

Fluzone

GSK

Preclinical

37 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

Crestor

AstraZeneca

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

COMIRNATY

Pfizer

Preclinical

1 8

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 9

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 10

Meningococcal Group ACYW135 (Conjugate) (MCV4)

CanSino Biologics Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Recruiting

Influenza

NCT07203755

Clinical

Trials by Indication[1]

Influenza1 trial

Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine

Recruiting· CanSino Biologics Inc. logo

CanSino Biologics Inc.·Phase 1·NCT07203755·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Meningococcal Group ACYW135 (Conjugate) (MCV4). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Meningococcal Group ACYW135 (Conjugate) (MCV4) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Meningococcal Group ACYW135 (Conjugate) (MCV4). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CanSino Biologics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CanSino Biologics Inc.

Meningococcal Group ACYW135 (Conjugate) (MCV4)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Influenza1 trial

References

Drug Info

Quick Facts

Related News